Microbot Medical (MBOT) Expected to Release Earnings on Tuesday

by · The Cerbat Gem

Microbot Medical (NASDAQ:MBOT – Get Free Report) is anticipated to announce its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.08) per share and revenue of $0.3330 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Microbot Medical (NASDAQ:MBOT – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.03. The firm had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.30 million. On average, analysts expect Microbot Medical to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Microbot Medical Trading Up 0.8%

Shares of Microbot Medical stock traded up $0.01 during trading on Tuesday, reaching $1.78. 241,481 shares of the stock were exchanged, compared to its average volume of 1,556,777. The company has a quick ratio of 21.93, a current ratio of 22.59 and a debt-to-equity ratio of 0.01. The firm has a market cap of $119.90 million, a price-to-earnings ratio of -6.87 and a beta of 1.06. Microbot Medical has a 1 year low of $1.60 and a 1 year high of $4.67. The stock’s fifty day moving average is $1.84 and its 200 day moving average is $2.08.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Loop Capital set a $4.00 price target on Microbot Medical in a research report on Wednesday, June 3rd. HC Wainwright reiterated a “buy” rating on shares of Microbot Medical in a research report on Tuesday, July 14th. Zacks Research upgraded shares of Microbot Medical from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 22nd. Wall Street Zen upgraded shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Microbot Medical in a research note on Wednesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Microbot Medical currently has an average rating of “Buy” and a consensus price target of $6.62.

View Our Latest Research Report on Microbot Medical

Hedge Funds Weigh In On Microbot Medical

Institutional investors and hedge funds have recently made changes to their positions in the business. Cetera Investment Advisers raised its position in shares of Microbot Medical by 38.8% in the 4th quarter. Cetera Investment Advisers now owns 29,313 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 8,201 shares during the last quarter. Zacks Investment Management purchased a new stake in Microbot Medical during the 3rd quarter valued at about $33,000. Squarepoint Ops LLC bought a new stake in Microbot Medical during the 3rd quarter valued at about $37,000. American Century Companies Inc. bought a new stake in Microbot Medical during the 2nd quarter valued at about $32,000. Finally, Wexford Capital LP purchased a new position in Microbot Medical in the third quarter worth about $50,000. Institutional investors own 16.30% of the company’s stock.

About Microbot Medical

(Get Free Report)

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.

Further Reading